189 related articles for article (PubMed ID: 36815858)
1. Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Selby PR; Heffernan AJ; Yeung D; Warner MS; Peake SL; Hahn U; Wallis SC; Mcwhinney B; Ungerer JPJ; Shakib S; Roberts JA
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0155022. PubMed ID: 36815858
[TBL] [Abstract][Full Text] [Related]
2. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.
Tängdén T; Cojutti PG; Roberts JA; Pea F
Clin Pharmacokinet; 2018 Nov; 57(11):1399-1405. PubMed ID: 29546589
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach.
Lalagkas PN; Iliou J; Rigo R; Miarons M; Fernández-Alarcon B; Bestard O; Cruzado JM; Melilli E; Torras J; Grinyó JM; Lloberas N; Colom H
Clin Pharmacokinet; 2023 Jun; 62(6):861-880. PubMed ID: 37140726
[TBL] [Abstract][Full Text] [Related]
6. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients.
Selby PR; Shakib S; Peake SL; Warner MS; Yeung D; Hahn U; Roberts JA
Clin Pharmacokinet; 2021 Jun; 60(6):727-739. PubMed ID: 33515202
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Ganciclovir in Critically Ill Patients.
Krens SD; Hodiamont CJ; Juffermans NP; Mathôt RAA; van Hest RM
Ther Drug Monit; 2020 Apr; 42(2):295-301. PubMed ID: 31425489
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis.
Jarrell AS; Crow JR; Strout SE; Kruer RM; Toman LP; Dioverti-Prono MV; Lees L; Avery RK; Marzinke MA
Clin Infect Dis; 2021 Jul; 73(1):101-106. PubMed ID: 32379860
[TBL] [Abstract][Full Text] [Related]
11. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection.
Tornatore KM; Garey KW; Saigal N; Reed K; Murray B; Ingalls E; DiFrancesco R; Forrest A; Morse G; Venuto R
Clin Transplant; 2001 Oct; 15(5):297-308. PubMed ID: 11678955
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens.
Nguyen T; Oualha M; Briand C; Bendavid M; Béranger A; Benaboud S; Tréluyer JM; Zheng Y; Foissac F; Winter S; Gana I; Boujaafar S; Lopez V; Berthaud R; Demir Z; Bouazza N; Hirt D
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318012
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
Vezina HE; Brundage RC; Balfour HH
Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring.
Ho SA; Slavin M; Roberts JA; Yong M
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):707-718. PubMed ID: 33201745
[No Abstract] [Full Text] [Related]
16. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
[TBL] [Abstract][Full Text] [Related]
17. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
Welker H; Farhan M; Humar A; Washington C
Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
19. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Cockcroft-Gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance.
Palacio-Lacambra ME; Comas-Reixach I; Blanco-Grau A; Suñé-Negre JM; Segarra-Medrano A; Montoro-Ronsano JB
Br J Clin Pharmacol; 2018 Sep; 84(9):2120-2128. PubMed ID: 29791023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
